XML 62 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Note 12 - Restructuring Charges
 12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]
12.
Restructuring Charges
 
In
April 2019,
the Board of Directors approved a plan (
“2019
Restructuring Program”) to reduce operating expenses as the Company evaluates its strategic alternatives following the release of top-line data from the PATENCY-
2
clinical trial of vonapanitase on
March 28, 2019.
The restructuring initiatives are company-wide. The remainder of the charges were incurred by the end of the fiscal year ended
December 31, 2019 (
“Fiscal Year
2019”
) and were paid during the year ended
December 31, 2019.
 
Changes in the restructuring accrual during the year ended
December 31, 2019
are summarized below (in thousands):
 
    As of
December 31, 2018		   Charges/
(Benefits)		   Payment/Other   As of
December 31, 2019
2019 Restructuring Program                                
Employee Severance   $
-
     $
2,854
     $
(2,854
 )   $
-
  
Total   $
-
     $
2,854
     $
(2,854
 )   $
-